 |
|
|
|
|
New MS Drug Target Shows Promise
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 "It needs to be tested in clinical trials. We need evidence, and these drugs have serious potential side effects," he said. "But organized, well-run clinical trials should be done, because these drugs may be of immense potential benefit to people with MS."
Praising the study's use of donated human samples, O'Looney added that, "it's a perfect example of how we can learn so much from the use of tissue samples. We are so indebted to people with MS who leave the message that their bodies are available to researchers. So, this is the perfect example of how valuable that is. That's what drove this study."
More information
Text Continues Below
For more on multiple sclerosis, visit the National Multiple Sclerosis Society.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 2/18/2008
|
|
SOURCES: Larry Steinman, M.D., professor, neurology and neurological sciences, and chair, Interdepartmental Program in Immunology, Stanford University School of Medicine; Patricia A. O'Looney, Ph.D., vice president of biomedical research, National Multiple Sclerosis Society; Feb. 17, 2008, advance online publication, Nature
|
.gif)
